Search

Multivalent Pneumococcal Conjugate Vaccine 21 Serotypes Sanofi

The USPTO issued Patent US12605435B2 to Sanofi Pasteur Inc. for a multivalent pneumococcal polysaccharide-protein conjugate composition covering 21 Streptococcus pneumoniae serotypes. The patent claims conjugates using tetanus toxoid and CRM197 carriers with application in prophylaxis against pneumococcal infection. The patent contains 15 claims and was granted on April 21, 2026.